Teleflex Stock Forecast, Price & News (NYSE:TFX)

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.31 out of 5 stars

183rd out of 986 stocks

17th out of 98 stocks

Teleflex has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 6 buy ratings, 6 hold ratings, and no sell ratings.

According to analysts' consensus price target of $273.38, Teleflex has a forecasted upside of 15.4% from its current price of $236.81.

Teleflex has only been the subject of 4 research reports in the past 90 days.

Teleflex has a dividend yield of 0.57%, which is in the bottom 25% of all stocks that pay dividends.

Teleflex does not have a long track record of dividend growth.

The dividend payout ratio of Teleflex is 17.73%. This payout ratio is at a healthy, sustainable level, below 75%.

Based on earnings estimates, Teleflex will have a dividend payout ratio of 9.35% next year. This indicates that Teleflex will be able to sustain or increase its dividend.

In the past three months, Teleflex insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $742,290.00 in company stock.

Only 1.41% of the stock of Teleflex is held by insiders.

93.82% of the stock of Teleflex is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Earnings for Teleflex are expected to grow by 9.41% in the coming year, from $13.29 to $14.54 per share.

The P/E ratio of Teleflex is 30.87, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 136.77.

The P/E ratio of Teleflex is 30.87, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 101.25.

Teleflex has a PEG Ratio of 2.55. PEG Ratios above 1 indicate that a company could be overvalued.

Teleflex has a P/B Ratio of 2.76. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. The company also offers interventional products, which consists of various coronary catheters, structural heart therapies, and peripheral intervention and cardiac assist products that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded catheters, Guideline, Turnpike, and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; and respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings. It provides urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. The company was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.

Sign-up to receive the latest news and ratings for Teleflex and its competitors with MarketBeat's FREE daily newsletter.

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Teleflex in the last year. There are currently 6 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TFX shares. View TFX analyst ratings or view top-rated stocks.

12 equities research analysts have issued 1 year price objectives for Teleflex's shares. Their TFX share price forecasts range from $210.00 to $330.00. On average, they anticipate the company's stock price to reach $273.38 in the next twelve months. This suggests a possible upside of 15.5% from the stock's current price. View analysts price targets for TFX or view top-rated stocks among Wall Street analysts.

Teleflex's stock was trading at $249.63 on January 1st, 2023. Since then, TFX shares have decreased by 5.2% and is now trading at $236.64. View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, July 27th 2023. View our TFX earnings forecast.

Teleflex Incorporated (NYSE:TFX) issued its earnings results on Thursday, May, 4th. The medical technology company reported $3.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.97 by $0.12. The medical technology company earned $710.90 million during the quarter, compared to analyst estimates of $687.11 million. Teleflex had a trailing twelve-month return on equity of 15.80% and a net margin of 12.68%. The business's revenue was up 10.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.88 earnings per share. Read the conference call transcript.

Teleflex declared a quarterly dividend on Monday, May 8th. Investors of record on Monday, May 15th will be given a dividend of $0.34 per share on Thursday, June 15th. This represents a $1.36 annualized dividend and a yield of 0.57%. The ex-dividend date is Friday, May 12th. Read our dividend analysis for TFX.

ETFs with the largest weight of Teleflex (NYSE:TFX) stock in their portfolio include First Trust Indxx Medical Devices ETF (MDEV), Invesco S&P 500 Equal Weight Health Care ETF (RYH), SPDR S&P Health Care Equipment ETF (XHE), iShares U.S. Medical Devices ETF (IHI), Mid Cap US Equity Select ETF (RNMC), Global X Aging Population ETF (AGNG), First Trust Health Care AlphaDEX Fund (FXH) and Timothy Plan US Large Cap Core ETF (TPLC).

Teleflex (NYSE:TFX) pays an annual dividend of $1.36 per share and currently has a dividend yield of 0.57%. The dividend payout ratio is 17.73%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, TFX will have a dividend payout ratio of 9.35% next year. This indicates that the company will be able to sustain or increase its dividend. Read our dividend analysis for TFX.

Teleflex updated its FY 2023 earnings guidance on Thursday, May, 4th. The company provided earnings per share guidance of $13.00-$13.60 for the period, compared to the consensus EPS estimate of $13.29. The company issued revenue guidance of $2.92 billion-$2.96 billion, compared to the consensus revenue estimate of $2.93 billion.

73 employees have rated Teleflex Chief Executive Officer Liam Kelly on Glassdoor.com. Liam Kelly has an approval rating of 86% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Teleflex investors own include NVIDIA (NVDA), AbbVie (ABBV), Johnson & Johnson (JNJ), Alibaba Group (BABA), Lam Research (LRCX), ServiceNow (NOW), QUALCOMM (QCOM), Advanced Micro Devices (AMD), Salesforce (CRM) and Cisco Systems (CSCO).

Teleflex trades on the New York Stock Exchange (NYSE) under the ticker symbol "TFX."

Teleflex's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.48%), Wellington Management Group LLP (6.60%), State Street Corp (4.96%), Price T Rowe Associates Inc. MD (3.90%), Geode Capital Management LLC (2.07%) and Allspring Global Investments Holdings LLC (1.80%). Insiders that own company stock include Andrew A Krakauer, Cameron P Hicks, Liam Kelly, Stephen K MD Klasko, Stephen K MD Klasko and Stuart A Randle. View institutional ownership trends.

Shares of TFX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.

One share of TFX stock can currently be purchased for approximately $236.64.

Teleflex (NYSE:TFX) has a market capitalization of $11.10 billion and generates $2.79 billion in revenue each year. The medical technology company earns $363.14 million in net income (profit) each year or $7.67 on an earnings per share basis.

The company employs 15,500 workers across the globe.

Teleflex's mailing address is 550 E SWEDESFORD RD, WAYNE PA, 19087. The official website for the company is www.teleflex.com. The medical technology company can be reached via phone at (610) 225-6800, via email at [email protected], or via fax at 215-553-5402.

You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist.

Please log in to your account or sign up in order to add this asset to your watchlist.

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.